(Q45129282)

9 December 2017

Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors (English)

1 reference

9 December 2017

0 references

8

1 reference

9 December 2017

Athanasios Dimopoulos

12

1 reference

9 December 2017

2

Dimitra Gika

1 reference

9 December 2017

5

Athanasios Zomas

1 reference

9 December 2017

10

Anna Tassidou

1 reference

9 December 2017

6

Anastasia Pouli

1 reference

9 December 2017

11

Dimitra Anagnostou

1 reference

9 December 2017

George Hamilos

3

1 reference

9 December 2017

Konstantinos Zervas

4

1 reference

9 December 2017

Markela Zorzou

7

1 reference

9 December 2017

Athanasios Anagnostopoulos

1

0 references

Nikolaos Anagnostopoulos

9

0 references

publication date

1 November 2004

1 reference

9 December 2017

1 reference

9 December 2017

45

1 reference

9 December 2017

11

1 reference

9 December 2017

2275-2279

1 reference

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

9 December 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190410001733772

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190410001733772

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190410001733772

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190410001733772

10.1080/10428190410001733772

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference